Ami Flores
Family Health · Chula Vista, CANPI 1215293345
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,112 of the $3,512 with a category attached, or 88.6%. It is spread thinly across 35 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,328 and has fallen 95.5% since, to $60 in 2025.
Across 138 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$373
- Merck$307
- Beigene USA, Inc.$267
- Blueprint Medicines Corporation$234
- Pharmacyclics LLC, An Abbvie Company$233
- GSK$225
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,11289%
- Education$40011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 14 | $373 |
| Merck | 15 | $307 |
| Beigene USA, Inc. | 5 | $267 |
| Blueprint Medicines Corporation | 6 | $234 |
| Pharmacyclics LLC, An Abbvie Company | 10 | $233 |
| GSK | 6 | $225 |
| Pfizer | 10 | $205 |
| AstraZeneca(2 entities) | 5 | $162 |
| Seagen Inc. | 6 | $128 |
| Sanofi | 5 | $121 |
| Amgen | 5 | $111 |
| Astellas Pharma US Inc | 2 | $110 |
| Eisai Inc. | 4 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $79 |
| Novartis | 3 | $77 |
| Puma Biotechnology, Inc. | 3 | $74 |
| Taiho Oncology, Inc. | 2 | $64 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Bayer | 3 | $59 |
| AbbVie | 3 | $53 |
| Gilead | 3 | $50 |
| Mirati Therapeutics, Inc. | 2 | $44 |
| Incyte Corporation | 2 | $43 |
| Bristol Myers Squibb | 2 | $43 |
| Myovant Sciences Inc. | 2 | $40 |
| Deciphera Pharmaceuticals Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $33 |
| Karyopharm Therapeutics Inc. | 1 | $33 |
| Octapharma USA, Inc. | 1 | $30 |
| Coherus Oncology, Inc. | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Genentech USA, Inc. | 2 | $24 |
| Foundation Medicine, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few family health providers in Californiato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $105,540 |
| OrgovyxRelugolix | 11 | $29,671 |
| EliquisApixaban | 12 | $13,427 |
| Tamoxifen Citrate | 13 | $538 |
| Ondansetron OdtOndansetron | 11 | $310 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $269 |
| Letrozole | 17 | $263 |
| Dexamethasone | 13 | $228 |
| Anastrozole | 15 | $179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Taiho Oncology, Inc.Lonsurf | $64 | $105,54012 claims |
| PfizerEliquis | $205 | $13,42712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in Californiaon file to place this against a meaningful peer group, so we don't.
Other family health in Chula Vista
- Marylyn HagertySan Clemente$3K
- Carrie ClarkLos Gatos$1K
- Karen GreenhawPenn Valley$702
- Jody ReifenbergerRamona$302
- Fazela WasimiSan Diego$228
- Christianna EspinozaSan Diego$155
- Arezou CroseRedding$125
- Riaz QamarFresno$110
- Luis TeoxonMaywood$75
- Leonor HuddlestonLos Angeles$26
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.